UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia.

Autor: Vivek K; Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK., Karagozlu Z; Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK., Erridge S; Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.; Department of Medicine, Curaleaf Clinic, London, UK., Holvey C; Department of Medicine, Curaleaf Clinic, London, UK., Coomber R; Department of Medicine, Curaleaf Clinic, London, UK.; Department of Trauma and Orthopaedics, St. George's Hospital NHS Trust, London, UK., Rucker JJ; Department of Medicine, Curaleaf Clinic, London, UK.; Department of Psychological Medicine, Kings College London, London, UK.; National and Specialist Tertiary Referrals Affective Disorders Service, South London & Maudsley NHS Foundation Trust, London, UK., Weatherall MW; Department of Medicine, Curaleaf Clinic, London, UK.; Department of Neurology, Buckinghamshire Healthcare NHS Trust, Amersham, UK., Sodergren MH; Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.; Department of Medicine, Curaleaf Clinic, London, UK.
Jazyk: angličtina
Zdroj: Brain and behavior [Brain Behav] 2024 Feb; Vol. 14 (2), pp. e3410.
DOI: 10.1002/brb3.3410
Abstrakt: Introduction: The primary aim of this study was to assess changes in sleep-specific health-related quality of life (HRQoL) for those prescribed cannabis-based medicinal products (CBMPs) for insomnia.
Methods: A case series of UK patients with insomnia was analyzed. Primary outcomes were changes in the Single-Item Sleep-Quality Scale (SQS), Generalized Anxiety Disorder-7 (GAD-7), and EQ-5D-5L at up to 6 months from baseline. Statistical significance was identified as a p value < .050.
Results: 61 patients were included in the analysis. There was an improvement in the SQS from baseline at 1, 3, and 6 months (p < .001). There were also improvements in the EQ-5D-5L Index value and GAD-7 at 1, 3, and 6 months (p < .050). There were 28 (45.9%) adverse events recorded by 8 patients (13.1%). There were no life-threatening/disabling adverse events.
Conclusion: Patients with insomnia experienced an improvement in sleep quality following the initiation of CBMPs in this medium-term analysis. Fewer than 15% of participants reported one or more adverse events. However, due to the limitations of the study design, further investigation is required before definitive conclusions can be drawn on the efficacy of CBMPs in treating insomnia.
(© 2024 The Authors. Brain and Behavior published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje